Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week. Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test. Conclusion: Higher GH doses result in a greater height gain and improved bone strength.
Influence of two different GH dosage regimens on final height, bone geometry and bone strength in GH-deficient children.
BOZZOLA, MAURO;
2006-01-01
Abstract
Subjects and methods: Final height; parentally adjusted final height; the metacarpal index (MI) SIB. the inner and outer diameters: and the total cross-sectional area (CSA). cortical CSA. medullary CSA and bone strength (Bending Breaking Resistance Index (BBRI)) were evaluated at the metacarpal site in two cohorts of GH-deficient children. treated with two different doses of GH. Group 1. (38 patients) was treated with 0.16 mg/kg body weight per week of GH and group 2 (37 patients) with 0.3 mg/kg per week. Results: At the end of treatment. with group 1 vs group 2. height SDS was -0.84 +/- 1.07 vs -0.46 +/- 0.76. and parentally adjusted height SDS was 0.14 +/- 1.08 vs 0.27 +/- 0.82. Parentally adjusted relative height gain was 1.14 +/- 0.89 vs 2.14 +/- 0.72 SDS (P < 0.000.1). MI SDS was 0.58 +/- 1.31. vs -0.42 +/- 1.54 (P < 0.005). MI SDS gain was 0.07 +/- 1.41 vs -0.35 +/- 1.85. There was no difference between groups in the outer and inner diameter, in the total and cortical CSAs, whereas medullary CSA was higher in group 2 (P < 0.05). BBRI was 10.02 +/- 5.37 vs 11.52 +/- 5.49cm(3), and BBRI gainwas 3.33 +/- 5.06 vs 6.88 +/- 6.65 (P=0.01). P values were assessed using student's t-test. Conclusion: Higher GH doses result in a greater height gain and improved bone strength.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
